INIS
patients
100%
mortality
100%
blood
61%
risks
61%
therapy
50%
anticoagulants
50%
hemorrhage
44%
transfusions
38%
ischemia
38%
losses
22%
comparative evaluations
16%
safety
11%
cost
11%
administration
11%
data
11%
information
11%
foundations
5%
medical centers
5%
usa
5%
guidelines
5%
Pharmacology, Toxicology and Pharmaceutical Science
Fibrinolytic Agent
50%
Cerebrovascular Accident
50%
Bleeding
50%
Tenecteplase
50%
Brain Ischemia
50%
Direct Oral Anticoagulant
50%
Mortality Rate
37%
Brain Hemorrhage
37%
Alteplase
12%
Retrospective Study
12%
Neuroscience
Tenecteplase
50%
Alteplase
50%
Stroke
50%
Thrombolytic Drug
50%
Antithrombotic
50%
Intracranial Hemorrhage
27%
Ischemic Stroke
16%
Randomized Controlled Trial
5%
